Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2008-01-22
2008-01-22
Hartley, Michael G. (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
active
07320968
ABSTRACT:
A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic ketone; the use of the composition to treat a condition, for example, male hypogonadism, in a patient by applying the composition to the membrane of the patient; and a method for making the composition.
REFERENCES:
patent: 4801586 (1989-01-01), Minaskanian et al.
patent: 4879275 (1989-11-01), Minaskanian et al.
patent: 5023252 (1991-06-01), Hseih
patent: 5270346 (1993-12-01), Minaskanian et al.
patent: 5731303 (1998-03-01), Hsieh
patent: 5968919 (1999-10-01), Samour et al.
patent: 6319913 (2001-11-01), Mak et al.
patent: 6495124 (2002-12-01), Samour
patent: 6503894 (2003-01-01), Dudley et al.
patent: 6980852 (2005-12-01), Jersey-Willuhn et al.
patent: 7198801 (2007-04-01), Carrara et al.
patent: 7214381 (2007-05-01), Carrara et al.
patent: 2002/0183296 (2002-12-01), Dudley et al.
patent: 2003/0022877 (2003-01-01), Dudley
patent: 2003/0050292 (2003-03-01), Dudley et al.
patent: 2003/0082227 (2003-05-01), Sournac et al.
patent: 2003/0139384 (2003-07-01), Dudley
patent: 2003/0216630 (2003-11-01), Jersey-Willuhn et al.
patent: 2003/0216663 (2003-11-01), Jersey-Willuhn et al.
patent: 2004/0002482 (2004-01-01), Dudley et al.
patent: 2004/0044086 (2004-03-01), Schulze et al.
patent: 2004/0198706 (2004-10-01), Carrara et al.
patent: 2004/0259784 (2004-12-01), White et al.
patent: WO 01/39754 (2001-06-01), None
patent: WO 02/17926 (2002-03-01), None
patent: WO 02/17927 (2002-03-01), None
patent: WO2004/037173 (2004-05-01), None
patent: WO2004/091631 (2004-10-01), None
Tamburic et al, An investigation into the rheological, dieectric and mucoadhesive properties of poly(acrylic acid) gel systems, Apr. 10, 1995, Journal of Controlled Release 37 (1995), pp. 59-68.
Dictionary definition of stabilizer, Academic Press Dictionary of Science and Tecnology from Elsevier Science and Technology,from www.xreferplus.com, (c)1992, 1996 by Academic Press.
“Bentley Pharmaceuticals Announced Research and Licensing Agreements for its Topical Testosterone Gel Formulation”, Jun. 6, 2000.
“Bentley Pharmaceuticals Announces License Agreement for its Topical Testosterone Gel Formulation; License is First for CPE-215 Permeation Technology”, Dec. 18, 2000.
Printout from “Tess” site summarizing Trademark Application for “CPE-215” filed Mar. 22, 2000.
Form S-3 Registration Statement Under the Securities Act of 1933, Bentley Pharmaceuticals, Inc., Feb. 15, 2002, pp. 31 to 36.
“Bentley Pharmaceuticals Announces Initiation of Phase III Clinical Study of Topical Testosterone Gel”, Mar. 20, 2001.
Barron Alexis
Bentley Pharmaceuticals, Inc.
Hartley Michael G.
Huang Gigi
Synnestvedt & Lechner LLP
LandOfFree
Pharmaceutical composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2799363